BR9914215A - Antagonistas de mglur5 para o tratamento da dor e da ansiedade - Google Patents

Antagonistas de mglur5 para o tratamento da dor e da ansiedade

Info

Publication number
BR9914215A
BR9914215A BR9914215-5A BR9914215A BR9914215A BR 9914215 A BR9914215 A BR 9914215A BR 9914215 A BR9914215 A BR 9914215A BR 9914215 A BR9914215 A BR 9914215A
Authority
BR
Brazil
Prior art keywords
pain
treatment
antagonists
anxiety
mglur5
Prior art date
Application number
BR9914215-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Hans Allgeier
Nicholas David Cosford
Peter Josef Flor
Fabrizio Gasparini
Conrad Gentsch
Stehphen D Hess
Edwin Carl Johnson
Rainer Kuhn
Mark Tricklebank
Laszlo Urban
Mark Andrew Varney
Goenuel Velicelebi
Katharine Walker
Original Assignee
Novartis Ag
Sibia Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9914215(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9821503.1A external-priority patent/GB9821503D0/en
Application filed by Novartis Ag, Sibia Neurosciences Inc filed Critical Novartis Ag
Publication of BR9914215A publication Critical patent/BR9914215A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
BR9914215-5A 1998-10-02 1999-09-30 Antagonistas de mglur5 para o tratamento da dor e da ansiedade BR9914215A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9821503.1A GB9821503D0 (en) 1998-10-02 1998-10-02 Organic compounds
US22081398A 1998-12-23 1998-12-23
PCT/EP1999/007239 WO2000020001A1 (en) 1998-10-02 1999-09-30 Mglur5 antagonists for the treatment of pain and anxiety

Publications (1)

Publication Number Publication Date
BR9914215A true BR9914215A (pt) 2001-07-03

Family

ID=26314451

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914215-5A BR9914215A (pt) 1998-10-02 1999-09-30 Antagonistas de mglur5 para o tratamento da dor e da ansiedade

Country Status (21)

Country Link
EP (1) EP1117403B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002526408A (cg-RX-API-DMAC7.html)
KR (1) KR20010088832A (cg-RX-API-DMAC7.html)
CN (1) CN1187048C (cg-RX-API-DMAC7.html)
AT (1) ATE255894T1 (cg-RX-API-DMAC7.html)
AU (1) AU765644B2 (cg-RX-API-DMAC7.html)
BR (1) BR9914215A (cg-RX-API-DMAC7.html)
CA (1) CA2345137A1 (cg-RX-API-DMAC7.html)
DE (1) DE69913548T2 (cg-RX-API-DMAC7.html)
DK (1) DK1117403T3 (cg-RX-API-DMAC7.html)
ES (1) ES2213389T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0200553A3 (cg-RX-API-DMAC7.html)
ID (1) ID29095A (cg-RX-API-DMAC7.html)
IL (2) IL142047A0 (cg-RX-API-DMAC7.html)
NO (1) NO20011440L (cg-RX-API-DMAC7.html)
NZ (1) NZ510743A (cg-RX-API-DMAC7.html)
PL (1) PL202906B1 (cg-RX-API-DMAC7.html)
PT (1) PT1117403E (cg-RX-API-DMAC7.html)
RU (1) RU2232017C2 (cg-RX-API-DMAC7.html)
SK (1) SK4382001A3 (cg-RX-API-DMAC7.html)
WO (1) WO2000020001A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0005700D0 (en) * 2000-03-09 2000-05-03 Glaxo Group Ltd Therapy
ATE297734T1 (de) 2000-12-22 2005-07-15 Hoffmann La Roche Tetrahydro-(benzo- oder thieno-)azepin-pyrazin und triazinderivative als mglur 1 antagonisten
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
SE0303418D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 1
SE0303419D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 11
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
DE102005062985A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln
DK2083811T3 (en) 2006-11-22 2017-01-30 Clinical Res Ass Llc PROCEDURES FOR TREATING DOWNS SYNDROME, FRAGILT X SYNDROME AND AUTISM
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8586581B2 (en) * 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
EP2557183A1 (de) 2011-08-12 2013-02-13 Siemens Aktiengesellschaft Verfahren zum Betrieb einer Konti-Glühe für die Verarbeitung eines Walzguts
WO2013164790A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
AU2016273751B2 (en) 2015-06-03 2020-04-02 F. Hoffmann-La Roche Ag Ethynyl derivatives
KR20200035035A (ko) 2017-07-31 2020-04-01 노파르티스 아게 코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
EP3459939A1 (en) 2017-09-26 2019-03-27 Pragma Therapeutics Novel heterocyclic compounds as modulators of mglur7
KR102027368B1 (ko) * 2018-05-29 2019-10-01 서울대학교산학협력단 통증의 강도를 측정하는 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2056983T3 (es) * 1988-03-21 1994-10-16 Boehringer Ingelheim Pharma Compuestos para inhibir la biosintesis de metabolitos de acido araquidonico derivados de lipoxigenasa.
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives

Also Published As

Publication number Publication date
CN1321087A (zh) 2001-11-07
DE69913548D1 (de) 2004-01-22
NO20011440L (no) 2001-05-15
SK4382001A3 (en) 2001-08-06
EP1117403B1 (en) 2003-12-10
HUP0200553A3 (en) 2002-11-28
AU6198499A (en) 2000-04-26
NZ510743A (en) 2003-10-31
KR20010088832A (ko) 2001-09-28
ES2213389T3 (es) 2004-08-16
EP1117403A1 (en) 2001-07-25
CA2345137A1 (en) 2000-04-13
JP2002526408A (ja) 2002-08-20
PL346876A1 (en) 2002-03-11
DE69913548T2 (de) 2004-09-23
IL142047A (en) 2007-09-20
IL142047A0 (en) 2002-03-10
HUP0200553A2 (hu) 2002-07-29
AU765644B2 (en) 2003-09-25
NO20011440D0 (no) 2001-03-21
ID29095A (id) 2001-07-26
PL202906B1 (pl) 2009-08-31
PT1117403E (pt) 2004-04-30
DK1117403T3 (da) 2004-04-13
RU2232017C2 (ru) 2004-07-10
WO2000020001A1 (en) 2000-04-13
CN1187048C (zh) 2005-02-02
ATE255894T1 (de) 2003-12-15

Similar Documents

Publication Publication Date Title
PT1117403E (pt) Antagonistas de mglurs para o tratamento da dor e ansiedade
BR0110968A (pt) Antagonistas dos receptores de il-8
EP1109542A4 (en) NITROSED AND NITROSYLATED ANTAGONISTS OF THE ALPHA ADRENERGIC RECEPTOR, COMPOSITIONS AND USES THEREOF
EE200000778A (et) 4-bensüülpiperidiinalküülsulfoksiidi heterotsüklid ja nende kasutamine NMDA retseptori alaliikide suhtes selektiivsete antagonistidena
DE60113100D1 (de) Emulsion und wasserabstossende zusammensetzung
PT1286923E (pt) Tratamento de materiais minerais
DE69928542D1 (de) 5ht2-agoniste zur behandlung des glaukoms
BR9814040A (pt) Agudo no pulmão com fibrose com antagonistas de avb6
EE200100243A (et) 5HT1 retseptori agonistid ja metoklopramiid migreeni raviks
NO20030213L (no) Anvendelse av D2/D3 reseptor-agonister for behandling av fibr omyalgi
BR9809071A (pt) Agentes farmacológicos
NO20025758D0 (no) Anvendelse av skrueviklet rörkonstruksjon i brönnmiljöet
MA24736A1 (fr) Indoles 2,3-substitues servant d'agents anti-inflammatoires et analgesiques
BR0314488A (pt) Composto, composição farmacêutica e métodos de tratamento
FR2815541B1 (fr) Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique
BR9808302A (pt) O uso de levobupivacaìna na cirurgia pediátrica
DE60132851D1 (de) Arzneimittel zur Vorbeugung, Erleichterung oder Behandlung von Hypertension
ATE266420T1 (de) Kombinationspräparat, das selektive nmda nr2b- antagonisten und cox-2 inhibitoren enthält
IS2143B (is) Píperasínómetýlbensamíð sem delta-ópíóíðviðtakagerandefni
BR9808299A (pt) O uso de levobupivacaìna ou ropivacaìna para o tratamento da enxaqueca
EE200100553A (et) Saredutandi ja selle farmatseutiliselt vastuvõetavate soolade kasutamine meeleoluhäirete, kohanemishäirete või segatüüpi ärev-depressiivsete häirete raviks või vältimiseks kasulike ravimite valmistamiseks
BR0006269A (pt) Aplicação de dialquilpolissulfetos para o amassamento de borrachas naturais e de sìntese
BR9804749A (pt) Tratamento de purido.
BR0110450A (pt) Uso de agonistas receptores d4 de dopamina seletivo para tratamento de disfunção sexual
CY1108053T1 (el) Ενωση της κυαμεμαζινης και ενος ατυπου νευροληπτικου

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL.8: A61K 31/44, A61K 31/4402, A61K 31/4418, A61P 25/00, A61P 25/04, A61P 25/18, A61P 25/24, A61P 29/00, A61P 43/00

Ipc: A61K 31/44 (2007.10), A61K 31/4402 (2007.10), A61K

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE INCIDE NO ARTIGO 8O, 11 E 25 DA LPI ( LEI 9279/96 )

B12B Appeal against refusal [chapter 12.2 patent gazette]